Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/194013
Title: | Revisiting the bioavailability of flavan-3-ols in humans: A systematic review and comprehensive data analysis |
Author: | Di Pede, Giuseppe Mena, Pedro Bresciani, Letizia Achour, Mariem Lamuela Raventós, Rosa Ma. Estruch Riba, Ramon Landberg, Rikard Kulling, Sabine Wishart, David S. Rodríguez-Mateos, Ana Crozier, Alan Manach, Claudine Del Rio, Daniele |
Keywords: | Compostos bioactius Flavonoides Bioactive compounds Flavonoids |
Issue Date: | 1-Feb-2023 |
Publisher: | Elsevier Ltd |
Abstract: | This systematic review summarizes findings from human studies investigating the different routes of absorption, metabolism, distribution and excretion (ADME) of dietary flavan-3-ols and their circulating metabolites in healthy subjects. Literature searches were performed in PubMed, Scopus and the Web of Science. Human intervention studies using single and/or multiple intake of flavan-3-ols from food, extracts, and pure compounds were included. Forty-nine human intervention studies met inclusion criteria. Up to 180 metabolites were quantified from blood and urine samples following intake of flavan-3-ols, mainly as phase 2 conjugates of microbial catabolites (n =97), with phenyl-γ-valerolactones being the most representative ones (n =34). Phase 2 conjugates of monomers and phenyl-γ-valerolactones, the main compounds in both plasma and urine, reached two peak plasma concentrations (Cmax) of 260 and 88 nmol/L at 1.8 and 5.3 h (Tmax) after flavan-3-ol intake. They contributed to the bioavailability of flavan-3-ols for over 20%. Mean bioavailability for flavan-3-ols was moderate (31 ±23%, n bioavailability values =20), and it seems to be scarcely affected by the amount of ingested compounds. While intra- and inter-source differences in flavan-3-ol bioavailability emerged, mean flavan-3-ol bioavailability was 82% (n =1) and 63% (n =2) after ()-epicatechin and nut (hazelnuts, almonds) intake, respectively, followed by 25% after consumption of tea (n =7), cocoa (n =5), apples (n =3) and grape (n =2). This highlights the need to better clarify the metabolic yield with which monomer flavan-3-ols and proanthocyanidins are metabolized in humans. This work clarified in a comprehensive way for the first time the ADME of a (poly)phenol family, highlighting the pool of circulating compounds that might be determinants of the putative beneficial effects linked to flavan-3-ol intake. Lastly, methodological inputs for implementing well- designed human and experimental model studies were provided. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.mam.2022.101146 |
It is part of: | Molecular Aspects of Medicine, 2023, vol. 89 |
URI: | https://hdl.handle.net/2445/194013 |
Related resource: | https://doi.org/10.1016/j.mam.2022.101146 |
ISSN: | 0098-2997 |
Appears in Collections: | Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
729945.pdf | 5.6 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License